A 60-year-old Japanese woman died of a cerebral hemorrhage three days after receiving the experimental Covid vaccine developed by Pfizer, a vaccine based on messenger RNA technology, the Japanese Ministry of Health announced on Tuesday; however, the government denies there is a link between vaccination and death, according to Reuters.
The woman was vaccinated on Friday and suffered a cerebral hemorrhage three days later, on Monday, according to the ministry. This is the first death reported by Japan following a Covid vaccination.
“Cerebral hemorrhage, suspected to be the cause, is relatively common among people between the ages of 40 and 60, and at this time, based on examples from abroad, there does not appear to be a link between cerebral hemorrhage and the coronavirus vaccine. (…) It may be a coincidence, but it is necessary to gather more information and make an assessment in future working groups “, is the opinion of the Japanese Ministry of Health, which quotes Tomohiro Morio, doctor advisor of government.
Being part of the same state apparatus, his opinion cannot be considered independent and impartial.
Pfizer’s representatives in Japan did not comment to the press following the death of the vaccinated woman. Pfizer said in November that the vaccine’s effectiveness is consistent across age and ethnic groups and that there are no major side effects.
Since the start of the vaccination campaign in December 2020 – January 2021 in most countries of the civilized world, serious side effects and hundreds of deaths have begun to occur as a result of vaccination, but both Pfizer and government authorities deny any link between vaccination and medical incidents recorded shortly thereafter.
The recommendation was that only people with serious health conditions should consult a doctor first, the rest of the world being considered fit for vaccination.
Japan is the last member of the Group of Seven Highly Industrialized Countries (G7) to start the vaccination campaign on February 17, 2021, after officially approving the Pfizer vaccine last month, the first anti-Covid serum to receive approval in the Japanese market.
Meanwhile, three shipments of the product developed by Pfizer and BioNTech were delivered to Tokyo.